||Dr Tobias Menne
||University of Birmingham
||Cancer Research UK and AstraZeneca
||Acute Lymphoblastic Leukaemia (ALL)
||Clinical Trial of an Investigational Medicinal Product
|UKCRN Study ID:
|Open to New Sites?
|Recruitment Start Date:
|Anticipated Recruitment End Date:
|CRCTU Trial Management Team:
||Early Drug Development Team
|Trial Email Adress:
This trial is to investigate the combination of selumetinib and dexamethasone in the treatment of relapsed/refractory acute lymphoblastic leukaemia (ALL) in both adults and children. The trial is specifically for patients who have an identified change (mutation) in a particular gene in their cancer’s DNA. Phase I is to find the most suitable dose of selumetinib to safely give with dexamethasone. Phase II will use this dose to find out how well the combination works.
Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible.
Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website (see the link below).
Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.